Coagulation Flashcards
1
Q
What is hemostasis?
A
A series of physiologic processes that prevent bleeding when a blood vessel is damaged and, at the same time, keep blood in a fluid state
2
Q
primary hemostasis
A
platelet plug formation
3
Q
secondary hemostasis
A
coagulation cascade
4
Q
fibrinolygsis
A
removal of clot
5
Q
What converts prothrombin to thrombinf?
A
prothrombinase complex
6
Q
What converts fibrinogen to fibrin
A
thrombin (IIa)
7
Q
What does thrombin do?
A
coagulation, platelet activation, factor 8 activation, fibrinolysis, antigcoagulation etc….
8
Q
What are natural inhibitors of coagulation? (inhibit clotting)
A
TFPI - binds factor 7a
Protein C serine protease - cleaves 5a, 8a
- cofactor protein S is crucial for its function
- both are vit K dependent
Antithrombin
- binds/inactivates serine proteases of the coaglation cascade
- activity augmented by heparin
9
Q
What vasodilates the vessel wall?
A
nitric oxide
prostacyclins
10
Q
What are anticoagulant properties that effect hte vessel wall?
A
heparan sulfate
thrombomodulin (protein C pathway)
TF pathway inhibotr
VW factor
11
Q
What are components of platelets?
A
membrane receports
stored components
thromboxane
12
Q
what is in the plasma?
A
VWF
13
Q
What are disrdoers of primary hemostasis?
A
disoders of blood vessels
VW disease
thrombocytopenias
platelet dysfunction
14
Q
What are bleeding sxs in disorders of primary hemostasis?
A
- Petechiae (pinpoint, nonraised intradermal hemorrhage)
- Easy bruising
- Epistaxis (nose bleeding)
- Menorrhagia (heavy menstrual bleeding)
- Unexpected pre or post operative bleeding
- Severe spontaneous bleeding
15
Q
function of VWF?
A
mediates platelet adhesion at sites of vascular injury by binding to connective tissue and platelets
binds and stabilizes factor 7
16
Q
What produces VWF?
A
vascular endothelium and stored in weibel palade bodies –> multimerization
17
Q
What degrades VWF?
A
ADAMTS13
18
Q
What is VW disease?
A
- Inherited bleeding disorder caused by deficiency or dysfunction of von Willebrand factor (VWF)
- Prevalence of symptomatic patients ~0.0023-0.01%
- Prevalence by screening populations to identify people with ~0.6-1.3%
- Autosomal inheritance
19
Q
What are initial screenings assays for VWD?
A
• VWF antigen (VWF:Ag) – Measures the amount of protein – Antigen level many not equal activity level • Ristocetin Cofactor Activity (VWF:RCo) – Activity of VWF that causes binding of VWF to platelets in the presence of ristocetin resulting in platelet agglutination – Measured by various assays – Large coefficient of variation • Factor VIII – Clot based assays
(blood doesn’t clot well)
20
Q
What are tests for sub-typing VWD?
A
Multimeric analysis of VWF • Type 1, 2N – all multimers are present • Type 2A and 2B – largest are missing • Type 2M – all multimer are present or increased largest • Type 3 – too little VWF to measure
Ristocetin-induced platelet aggregation (RIPA):
• Differentiates Type 2A from 2B
• Increased sensitivity to ristocetin (“gain of function”) = Type 2B
21
Q
What is bleeding time?
A
• Cutismadeinforearm,earlobe,orfingertip blot with filter paper
measure bleeding time when bleeding stops
Disadvantages
• Labor intensive
• Accuracy depends on operator skills
• Hard to standardize
• Not a specific indicator of platelet function
• Poor indicator of surgical bleeding risk!
• ShouldnotbeusedasascreenforVWD!
22
Q
What are the classificaitons of VWD subtypes?
A
1 Partial quantitiative def of VWF 2 Qualittative VWF defect 2A No large multivers 2B No large multivers 2M Multivers are normal or incraesed high molecular weight 2N decreased affinity for factor 7 3 Deficiency of VWF
23
Q
What is hte prevalence of VWD subtypes?
A
1 60-80%
2 7-30%
3 5-20%
24
Q
14 y/o female with menorrhagia
VWF:AG 28% low
VWF:RCo 27% low
Multimer analysis: all multimer sizes present
Diagnosis?
A
T1 VWD
25
5yo boy w/ frequent nose bleeds
VWF:Ag normal
VWF:RCo LOW
Multimer analysis: large multimers are mising
Ristocetin induced platelet aggregation study POSITIVE
2A or 2B (large multimers missing)
2B: POSITVE ristocetin
often has decreased platelet count
26
What are the functions of platelets?
• Adhere to sites of vascular injury
– Glycoprotein Ia/IIa + collagen
– Glycoprotein Ib/IX/V + von Willebrand factor
• Release contents from granules
– Dense granules
• 2-7 per platelet
• ADP, ATP, calcium, serotonin
-- Alpha granules=
• 50-80 per platelet
• PDGF, insulin like growth factor 1, TGFβ, platelet factor 4, thrombospondin, fibrinogen, von Willebrand factor, fibronectin, factor V
• Express P-selectin and CD63
27
Platelet functions?
• Aggregate together to form a hemostatic platelet plug
– Glycoprotein IIb/IIIa + fibrinogen
– Glycoprotein Ib + von Willebrand factor
• Procoagulant surface for activated coagulation protein complexes on the phospholipid membrane
28
What are antiplatelet drugs?
cyclooxygenase - aspirin
ADP receptor/P2Y12 inhibitors - clopidogrel, prasugrel, ticagrelor, ticlodipine
glycoprotein IIb/IIa- abciximab, epitifibatide, tirofiban
phophodisterzase - cilostazol
adenosine reuptake - dipyridamole
29
What is a PFA?
• Measures closure time
• Simulatesprimaryhemostasisbycreatinghigh shear flow in capillary tube
• Membrane coated with agonists: – Collagen and ADP (C/ADP)
– Collagen and epinephrine (C/EPI)
• Plateletsgetactivatedbytheagonistsatthe membraneadhere on the membrane surfaceaperture is occluded by the platelet plug
• Instrumentsensesthetimeittakesbloodflowto stop
30
What is secondary hemostasis?
coagulation cascade
| series of enzymatic steps to amplify a minor insult into formation of a fibrin plu
31
What proteases and cofactors are responsible for secondary hemostasis?
• Serine proteases with different protein domains
– Factors XII, XI, X, IX, VII,II (prothrombin), XIII
• Cofactors - Factors V, VIII, tissue factor
– Enhance the efficiency of the coagulation factors
32
What initiates coagulation?
* Tissue Factor (TF) and Factor VII binding
* TF expressed on damaged or stimulated cells
* <5% Factor VII circulates in activated (VIIa) form
* Forms a complex in the presence of calcium
* Converts Factor X to Xa directly or indirectly through Factor IX to IXa conversion
33
What are contact factors?
Prekallikrein (PK) is a serine protease that complexes with the cofactor high molecular weight kiniogen (HMWK)
PK is cleaved by factor 12a > kallikrein > activation of kinin pathway
34
What does factor XI do?
Activates factor 9
| Activated by factor 12 and thrombin (creates a feedback loop)
35
What forms the xase complex?
* Factor IXa forms a complex with Factor VIIIa as cofactor
* Calcium ions required
* On a phospholipid surface • Activates Factor X to Xa
36
What forms the prothrombinase complex?
Factor Xa binds to Va as cofactor • Calcium ions required
• On a phospholipid surface
• Converts prothrombin (Factor II) to thrombin (Factor IIa)
37
What activates factor 8?
circulates as inactive form bound to VWF
activated by thrombin and factor Xa
38
What activates factor 5?
– Activated by several factors including thrombin, Factor Xa, plasmin, and others
– Can serve as a cofactor for Factor Xa without activation
39
What does thrombin do?
• Converts fibrinogen to fibrin
• No cofactor for enzymatic function needed
• Soluble fibrinogen cleaved by
thrombin turns to insoluble fibrin clot
– Thrombin cleaves off fibrinopeptide A and B from fibrinogen
– Fibrin monomers spontaneously polymerize to fibrin polymers
– Factor XIII stabilizes the clot by forming glutamyl-lysine bridges
40
What regulates thrombin?
* Positive feedback by activating Factors V, VIII, XI and XIII
* Negative feedback by activating Protein C and fibrinolysis
* Activates platelets
41
What is the testing principle to screen for coagulation disorders?
• Collect sample in citrate containing tube
binds Ca2+blocks clot formation
• Centrifuge to separate plasma from
cellular elements
• Plasma + add calcium to overwhelm
citratestarts clot formation
– Add additional factors to speed up process
and drive down a particular pathway
• Measure how long it takes to form a clot
42
APTT
Intrinsic pathway
43
PT/INR
Extrinsic pathwayy
44
Thrombin time
common pathway
45
What is PT
* Measures the time (seconds) from VIIa/TF binding to clot formation
* Thromboplastin reagent (Tissue factor + phospholipid) + Calcium added to citrated plasma
* Tests the EXTRINSIC and COMMON pathways
* Used commonly to monitor warfarin therapy
46
When is hte extrinsic pathway initiated?
when blood is exposed to TF on damaged endothelium
--> PT assay
47
What can cause a prolonged PT?
Inhibitor of Factor X, VII, V, II, or fibrinogen
Antiphospholipid antibodies, such as Lupus anticoagulants
Medications
Warfarin (a vitamin K antagonist)
Heparin (only at very high levels)
Anti-Xa inhibitors (e.g. Rivaroxaban, Apixaban, Edoxaban)
Direct thrombin inhibitors (eg. Dabigatran, Bivalirudin, Argatroban)
Liver disease
Consumption of factors as may be seen with disseminated
intravascular coagulation (DIC) or bleeding Dilution
Vitamin K deficiency
Dysfibrinogenemia
“Crap in a tube” = underfill, contamination from IV fluids, contamination from heparin in line, delay in testing, collecting in wrong tube, etc.
48
Why was INR developed?
to standardize PT testing and monitor pts on warfarin therapy
49
INR formula
INR = sample PT/mean PT x ISI
50
What is aPTT?
* Measuresthetime(seconds)clotformsthrough the activation of the contact and intrinsic pathways to clot formation
* Citratedplasmaismixedwithphospholipid (partial thromboplastin) and a contact activator + calcium
* TeststheINTRINSICandCOMMONpathways
* Used commonly to monitor unfractionated heparin therapy
51
What initiates aPTT measurement?
activation of FXII and contact factors on negatively charged phospholipid surfaces
52
What causes a prolonged aPTT?
• Inhibitor of Factor XII, XI, X, IX, VIII, V, II, or fibrinogen
• Deficiency of Prekallikrein and High Molecular Weight Kininogen (may not always be detected)
• Von Willebrand disease (due to low Factor VIII)
• Antiphospholipid antibodies, such as Lupus anticoagulants
• Medications
– Warfarin (a vitamin K antagonist) – Heparin
– Anti-Xa inhibitors (e.g. Rivaroxaban, Apixaban, Edoxaban)
– Direct thrombin inhibitors (e.g. Dabigatran, Bivalirudin, Argatroban)
• Liver disease
• Consumption of factors as may be seen with disseminated intravascular coagulation (DIC) or bleeding
• Dilution
• Vitamin K deficiency
• Dysfibrinogenemia
• “Crap in a tube” = underfill, contamination from IV fluids, contamination from heparin in line, delay in testing, collecting in wrong tube, etc.
53
What is used to assess the common pathway?
V, X, II, fibrinogen
Russel viper venom
activates factor X directly
DRVVT assay
54
What does TT measure?
* Measures the conversion of fibrinogen to fibrin (last step in the aPTT, PT/INR, and DRVVT)
* Detects abnormalities in fibrinogen to fibrin conversion
55
What causes a prolonged TT?
– Hypofibrinogenemia
– Dysfibrinogenemia
– Unfractionated heparin
– Direct thrombin inhibitors (hirudin, argatroban, dabigatran) – Fibrin degradation products (e.g. D-Dimer)
56
What has no effect on thrombin time?
– Warfarin
– Direct Xa inhibitors
– Factor II (factor 2) deficiency
57
Ho do you determine if a pt has a factor deficiency vs an inhibitor?
mixing study!
Mix pt plasma w/ normal plasma.
If aPTT corrects --> factor deficiency
If aPTT does NOT correct --> inhibitor
58
inheritance for hemophilia A and B?
x-linked recessive
59
Hemophilia A
```
def factor 8
1/5000 live male births
```
60
hemophilia B
```
def factor 9
1/30,000 live male births
```
61
what percentage of hemophilia A are new spontaneous mutations?
30%
62
What are clinical featurs of hemophilia A and B?
Intra-articular bleedings
– knees, elbows, ankles, shoulders, wrists
• Intramuscular hemorrhage 30% of bleeding events (compartment syndrome)
• Hematuria
• Intracranial hemorrhage (50% are spontaneous in adults)
• Gastrointestinal and oropharyngeal bleeding
63
How do you diagnosis w/ lab tests hemophilias?
• Isolated prolongation of aPTT
• Specific clotting factor assays are used for diagnosis (Factor VIII or IX)
– Severe <1%
– Moderate 1-5% – Mild 5-30%
• Can not distinguish Hemophilia A and B without labs
64
What is dyfibrinogenemia?
Protein does not function properly
• May be asymptomatic, hemorrhagic, or thrombotic
• Functional assays (activity) show lower level than antigen assays
• May or may not prolong clot times
65
Causes of elevated fibrinogen levels?
increasing age, females, pregnancy, acute phase reaction, smoking, exercise
66
Causes of reduced fibrinogen levels?
congenital, liver disease, disseminated intravascular coagulation (DIC), dilution, fibrinolysis
67
What is Owren's disease (factor V)?
acquired associated with exposure ot bovin thrombin in cardiac surgery
68
How do you treat factor VII (alexander's)
Treate with NovoSeven (recombinant FVIIa)
69
How do you treat factor X def?
Prothrombin complex concentrates
associated wtih amyloidosis
acquired form is more common
70
Factor XI def?
– 1 in 100,000
– Usually mild bleeding disorder
– FXI level does not correlate as well with bleeding tendency
– Bleeding
• Primarily trauma related
• Surgical bleeding at sites with fibrinolytic activity (tooth extraction, tonsillectomy, nasal surgery, prostatectomy)
71
FActor XII def?
1 in 1 million
| NO clinical signficance
72
What does factor XIII do?
crosslinks strands of fibrin -> stabilizes clot (fbirin stabilizing factor)
73
Sxs of factor XIII def
– Delayed bleeding, 12-36 hour after trauma
• Umbilical stump
• Bleeding after circumcision
• Spontaneous intra-cranial bleeding
• Superficial bruising, subcutaneous hematomas – Miscarriages
– Poor wound healing
74
How do you test for factor XIII def?
• Standard screening tests (PT, aPTT,
TT) are normal!!
• Screening test: clot solubility test (dissolve the clot with 5M urea or acid)
• Confirm with FXIII antigen or activity test
75
A patient has a prolonged PTT but normal PT and TT. Which of the following may explain this set of results?
A. Factor II (Factor 2) deficiency B. Factor V (Factor 5) deficiency C. Factor VII (Factor 7) deficiency D. Factor IX (Factor 9) deficiency
Factor 9
76
A patient has a prolonged INR and PTT, but normal TT. Which of the following may explain this set of results?
A. Fibrinogen deficiency
B. Factor V (Factor 5) deficiency
C. Factor VIII (Factor 8) deficiency D. Factor XIII (Factor 13) deficiency
Factor 5
77
Thrombin forms clot formation/thrombosis where as PLASMIN causes...
clot lysis/bleeding
Fibrinolysis
78
What is plasmin?
• Plasminogen --> plasmin
• Proteolytic enzyme
• Activated by thrombin
• Degrades cross-linked fibri > fibrin degradation products (FDP) appear in circulation
79
What is a d dimer?
a fibrin degradation product
80
What regulates fibrinolysis?
plasminogen is activated by tPA
81
What is tPA?
– synthesized in endothelial cells
– half life about 5 min
– inhibited by plasminogen activator inhibitor-1 (PAI-1)
82
What does alpha-2 plasmin inhibiotr do?
inhibits plasmin in circulation
83
What are the TEG parameteres?
• Rtime
– Measuresthetimetofibrinformationwithinaclot
– Determinedbyclottingfactorsandinhibitorbalance(eg.heparin)
• angle
– Anglebetweentheinitialslopeofthetracingandthehorizontal – Representsspeedofclotstrengtheningbyfibrincross-linkage
•K
– TimefromtheendofRuntiltheclotreaches20mm – Representsthespeedofclotformation
• Maximum amplitude (MA)
– Thestrengthoftheclot
– Dependsontheintegrityofplateletfunctionandfibrinogenbinding
• Ly30 and Ly60
– Lysis of the clot at 30 minutes and 60 minutes
• Coagulation Index (CI)
– Overallassessmentofcoagulation
– CI = −0.6516R − 0.3772K + 0.1224MA + 0.0759α − 7.7922
– Values +3.0 = hypercoagulable
84
What is platelet mapping?
Compares maximum amplitudes of response to various agonists
– Baseline = MATHROMBIN
– Activator (Reptilase + Factor XIII) = MAFIBRIN
– Activator +ADP = MAADP
• Used for ADP receptor inhibitors (e.g. clopidogrel)
– Activator + Arachidonic Acid = MAAA
• Used for Aspirin
